4.7 Review

Regulation of autophagy as a therapeutic option in glioblastoma

期刊

APOPTOSIS
卷 26, 期 11-12, 页码 574-599

出版社

SPRINGER
DOI: 10.1007/s10495-021-01691-z

关键词

Glioblastoma; Autophagy inhibition; Autophagy promotion; Monotherapy option; Combination therapy option; Apoptosis

资金

  1. National Institutes of Health (Bethesda, MD, USA) [CA-091460, NS-057811]
  2. South Carolina Honors College Research Program (Columbia, SC, USA)
  3. University of South Carolina Magellan Scholar Research Program (Columbia, SC, USA)

向作者/读者索取更多资源

Glioblastoma is the most common primary brain tumor in adults, with a dismal prognosis and limited treatment advancements in recent years. Therapies focusing on modulation of autophagy have been developed, leading to controversy between autophagy inhibition and promotion as strategies to control glioblastoma growth.
Around three out of one hundred thousand people are diagnosed with glioblastoma multiforme, simply called glioblastoma, which is the most common primary brain tumor in adults. With a dismal prognosis of a little over a year, receiving a glioblastoma diagnosis is oftentimes fatal. A major advancement in its treatment was made almost two decades ago when the alkylating chemotherapeutic agent temozolomide (TMZ) was combined with radiotherapy (RT). Little progress has been made since then. Therapies that focus on the modulation of autophagy, a key process that regulates cellular homeostasis, have been developed to curb the progression of glioblastoma. The dual role of autophagy (cell survival or cell death) in glioblastoma has led to the development of autophagy inhibitors and promoters that either work as monotherapies or as part of a combination therapy to induce cell death, cellular senescence, and counteract the ability of glioblastoma stem cells (GSCs) for initiating tumor recurrence. The myriad of cellular pathways that act upon the modulation of autophagy have created contention between two groups: those who use autophagy inhibition versus those who use promotion of autophagy to control glioblastoma growth. We discuss rationale for using current major therapeutics, their molecular mechanisms for modulation of autophagy in glioblastoma and GSCs, their potentials for making strides in combating glioblastoma progression, and their possible shortcomings. These shortcomings may fuel the innovation of novel delivery systems and therapies involving TMZ in conjunction with another agent to pave the way towards a new gold standard of glioblastoma treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据